{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:07Z","timestamp":1792652107108,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200183"],"award-info":[{"award-number":["82200183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Menin inhibitors (MENINis) represent a novel and promising class of therapeutic agents for acute leukemia (AL). AL subtypes driven by overexpressed\n                    <jats:italic>HOXA9\/MEIS1<\/jats:italic>\n                    , such as those characterized by\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -rearranged (\n                    <jats:italic>KMT2Ar<\/jats:italic>\n                    ) or\n                    <jats:italic>NPM1<\/jats:italic>\n                    -mutated (\n                    <jats:italic>NPM1m<\/jats:italic>\n                    ) AL, display sensitivity to MENINi. Consequently, approximately 40\u201350% of acute myeloid leukemia (AML) and 5\u201315% of acute lymphoblastic leukemia (ALL) patients may potentially benefit from MENINi-based therapy. At the 2024 ASH annual meeting, updated clinical data regarding monotherapy with MENINis in AL, including revumenib, bleximenib, enzomenib and BN104, were presented. Moreover, combination therapies based on MENINis were also reported to be highly effective in refractory\/relapsed, or newly diagnosed\n                    <jats:italic>KMT2Ar<\/jats:italic>\n                    - and\n                    <jats:italic>NPM1m<\/jats:italic>\n                    -AML patients. Evidently, MENINis have demonstrated a considerable efficacy in\n                    <jats:italic>KMT2Ar<\/jats:italic>\n                    - and\n                    <jats:italic>NPM1m<\/jats:italic>\n                    -AML patients with a well-tolerance. Furthermore, the therapeutic effects of venetoclax plus azacitidine or \"3\u2009+\u20097\" regimens were further enhanced by the addition of MENINis in\n                    <jats:italic>KMT2Ar<\/jats:italic>\n                    - and\n                    <jats:italic>NPM1m<\/jats:italic>\n                    -AML patients. Therefore, MENINis offer new therapeutic prospects for AML patients, particularly for those with high-risky and poor-prognostic on-target subtypes.\n                  <\/jats:p>","DOI":"10.1186\/s40164-025-00668-x","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:07:00Z","timestamp":1747894020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting"],"prefix":"10.1186","volume":"14","author":[{"given":"Jiewen","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"9","key":"668_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, et al. Therapeutic implications of Menin Inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201395.","journal-title":"Leukemia"},{"issue":"1","key":"668_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"VG Kalyan","year":"2024","unstructured":"Kalyan VG, Nadiminti, et al. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17(1):113.","journal-title":"J Hematol Oncol"},{"key":"668_CR3","doi-asserted-by":"crossref","unstructured":"Ibrahim, Aldoss et al. Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) KMT2Ar Acute Leukemia. Blood.2024;144 (Supplement 1):211.","DOI":"10.1182\/blood-2024-194384"},{"key":"668_CR4","doi-asserted-by":"crossref","unstructured":"Emma, Searle et al. Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations. Blood.2024;144(Supplement 1):212.","DOI":"10.1182\/blood-2024-207106"},{"key":"668_CR5","doi-asserted-by":"crossref","unstructured":"Joshua F, Zeidner, et al. Phase 1 results: First-in-Human phase 1\/2 study of the Menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Volume 144. Blood; 2024. p. 213. Supplement 1.","DOI":"10.1182\/blood-2024-194827"},{"key":"668_CR6","doi-asserted-by":"crossref","unstructured":"Depei, Wu, et al. A First-in-Human phase 1\/2 study of the Menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Volume 144. Blood; 2024. p. 2879. Supplement 1.","DOI":"10.1182\/blood-2024-198959"},{"key":"668_CR7","unstructured":"Ghayas C, Issa, Blood et al. 2024;144 (Supplement 1):216."},{"issue":"Supplement 1","key":"668_CR8","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1182\/blood-2024-199170","volume":"144","author":"T Amir","year":"2024","unstructured":"Amir T, Fathi, et al. Zfitomenib combined with Venetoclax\/Azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144(Supplement 1):2880.","journal-title":"Blood"},{"issue":"Supplement 1","key":"668_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2024-198218","volume":"144","author":"M Amer","year":"2024","unstructured":"Amer M, Zeidan, et al. Ziftomenib combined with intensive induction (7 + 3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144(Supplement 1):214.","journal-title":"Blood"},{"issue":"Supplement 1","key":"668_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2024-207072","volume":"144","author":"C Recher","year":"2024","unstructured":"Recher C, et al. Phase 1b study of Menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations. Blood. 2024;144(Supplement 1):215.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00668-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:07:09Z","timestamp":1747894029000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00668-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00668-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}